| 发明名称 | Use of IL-15 preparations to treat lymphopenia | ||
| 摘要 | The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15. | ||
| 申请公布号 | US8871191(B2) | 申请公布日期 | 2014.10.28 |
| 申请号 | US201013390504 | 申请日期 | 2010.08.13 |
| 申请人 | The United States of America as represented by the Secretary of the Department of Health and Human Services | 发明人 | Pavlakis George N.;Felber Barbara K.;Valentin Antonio;Bergamaschi Cristina |
| 分类号 | A61K38/20;A61K47/48;C07K14/54;A61K45/06;A61K38/17;A61K48/00;C12N15/85 | 主分类号 | A61K38/20 |
| 代理机构 | Kilpatrick Townsend & Stockton LLP | 代理人 | Kilpatrick Townsend & Stockton LLP |
| 主权项 | 1. A method of treating lymphopenia in an individual in need thereof comprising systemically administering to the individual a heterodimer comprising (i) an interleukin-15 (IL-15) and (ii) an IL-15Rα-Fc fusion protein that comprises a soluble IL-15Rα fused to an Fc region; wherein the IL-15 has at least 95% amino acid sequence identity to the region of SEQ ID NO:2 that corresponds to mature IL-15; and the IL-15Rα-Fc fusion protein comprises an amino acid sequence that has at least 95% amino acid sequence identity to the IL-15Rα-Fc fusion protein sequence of SEQ ID NO:17 or SEQ ID NO:20; wherein the heterodimer is administered at a dose that maintains supraphysiological plasma levels of IL-15 for two or more days. | ||
| 地址 | Washington DC US | ||